MATTHIAS KRETZLER, MD
Osteopathic Medicine in Ann Arbor, MI
License number
Michigan 4301086946
Category
Osteopathic Medicine
Type
Nephrology
License number
Michigan 4301086946
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1500 Floor Taubman Ctr, Ann Arbor, MI 48109
Phone
(734) 936-5548
(734) 936-2047
(734) 936-2047
Personal information
See more information about MATTHIAS KRETZLER at radaris.comName
Address
Phone
3435 Andover Rd, Ann Arbor, MI 48105
Ann Arbor, MI
3435 Andover Rd, Ann Arbor, MI 48105
Organization information
See more information about MATTHIAS KRETZLER at bizstanding.comMatthias Kretzler MD
1500 E Medical Ctr Dr, Ann Arbor, MI 48109
Industry:
Internist
Phone:
(734) 936-5548 (Phone)
Matthias Kretzler
Professional information
Dr. Matthias Kretzler - MD (Doctor of Medicine)
Hospitals:
1500 E Medical Center Dr, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
1500 E Medical Center Dr, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
1500 E Medical Center Dr, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
Education:
Medical Schools
Ruprecht-Karls-Universitaet Heidelberg, Medizinische Gesamtfakultat
Graduated: 1992
Ruprecht-Karls-Universitaet Heidelberg, Medizinische Gesamtfakultat
Graduated: 1992
Matthias Kretzler, Ann Arbor MI
Specialties:
Nephrologist
Address:
1500 E Medical Center Dr, Ann Arbor, MI 48109
Ilk Inhibitors For The Treatment Of Renal Disease
US Patent:
2008000, Jan 3, 2008
Filed:
Sep 14, 2007
Appl. No.:
11/855884
Inventors:
Matthias Kretzler - Ann Arbor MI, US
Patricia Logan - Vancouver, CA
Patricia Logan - Vancouver, CA
Assignee:
QLT INC. - Vancouver
International Classification:
A61K 31/7088, A61K 38/02, A61K 39/395, A61P 13/12
US Classification:
424130100, 514012000, 514044000
Abstract:
The invention relates to the treatment of renal diseases using modulators of integrin linked kinase. Methods of treatment as well as therapeutic agents including antisense, small molecules, catalytic peptides and antibodies are disclosed. The agents of the invention may also be used in combination with traditional therapies for renal disease including ACE inhibitors. An advantage of the invention is that it treats one of the causes of renal disease, rather than just ameliorating symptoms, and can help prevent the progression of renal disease to the point of acute renal failure.